Stealth's lead drug flunks again, this time in an eye disease, but biotech will attempt to push forward

Kyle LaHucik

Senior Reporter

Stealth BioTherapeutics’ lead drug has failed a Phase II study in an eye disease, dealing another blow to the biotech’s elamipretide as the treatment had …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Stealth's lead drug flunks again, this time in an eye disease, but biotech will attempt to push forward

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

European drug regulator reverses opinion on Eisai and Biogen's Alzheimer's drug

Gilead will close Philadelphia, Seattle offices as part of job reductions

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Stealth's lead drug flunks again, this time in an eye dis­ease, but biotech will at­tempt to push for­ward

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Stealth's lead drug flunks again, this time in an eye disease, but biotech will attempt to push forward

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

European drug regulator reverses opinion on Eisai and Biogen's Alzheimer's drug

Gilead will close Philadelphia, Seattle offices as part of job reductions

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?